Patience > FOMO: KNSA Shows the Playbook

On July 7, Kiniksa Pharmaceuticals (KNSA) hit our radar as a growth biotech with strong sales momentum:

• Arcalyst revenue up 73% YoY

• FY revenue guidance raised to ~$598M

• Building analyst support on sustained execution

We set an Accumulation Zone at $26–$27 and a Growth Target of $35+.

Crucially, KNSA didn’t enter our buy zone until late July. Instead of chasing, we waited.

That discipline matters: entering in the $26–$27 range positioned us to ride the move as KNSA approaches our profit target.

📈 The Lesson: Let Price Come to You

• Avoid FOMO: Quality setups often revisit your levels.

• Respect the Zone: Buy zones prevent overpaying and chasing peaks.

• Patience > Impulse: Boring entries, better outcomes.

KNSA July 7th Recap:

• Accumulation Zone: $26–$27 ✅

• Growth Target: $35+ 🎯 (nearly there)

• Catalysts: Quarterly earnings, analyst upgrades, technical breakout continuation

• Risk: Single‑product dependency (Arcalyst)

Takeaway: A repeatable process beats hot takes. Patience turned this watchlist name into a high‑conviction winner.

— StocksTrades.AI Newsletter

P.S. Want entries like this delivered to your inbox Monday through Friday? Upgrade here.

Disclaimer: This newsletter is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.